Design Therapeutics to Participate in 2026 Cantor Fitzgerald Global Healthcare Conference
Design Therapeutics (DSGN)/b) announced that its management will participate in a fireside chat at the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. ET in New York.
Rhea-AI Summary
Design Therapeutics (DSGN)/b) announced that its management will participate in a fireside chat at the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. ET in New York.A live webcast will be accessible via the investors section of the company’s website, and the replay will be archived for at least 30 days.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 03 | Earnings and trial update | Positive | +4.8% | RESTORE-FA update accompanied second-quarter results and revised dosing and endpoint plans. |
| Jun 30 | Trial dosing initiation | Positive | +1.6% | Patient dosing began in Phase 1 DT-818 multiple-ascending-dose trial for DM1. |
| May 28 | Conference participation | Neutral | -3.2% | Company announced participation in Jefferies healthcare conference fireside chat and webcast. |
| May 18 | Clinical data release | Positive | -25.5% | Four-week RESTORE-FA data reported clinical improvements and dose-dependent biomarker activity. |
| May 17 | Investor webcast notice | Neutral | -25.5% | Company scheduled webcast to review upcoming RESTORE-FA trial data with investors. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical reactions were mixed, with negative moves following the May conference notice and clinical-data release, while August and June updates aligned positively.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 9, 2026, at 2:45 p.m. ET in New York.
A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com.The webcast will be archived for at least 30 days following each presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck, THRUST
renee@thrustsc.com
